JP2020505044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505044A5 JP2020505044A5 JP2019540095A JP2019540095A JP2020505044A5 JP 2020505044 A5 JP2020505044 A5 JP 2020505044A5 JP 2019540095 A JP2019540095 A JP 2019540095A JP 2019540095 A JP2019540095 A JP 2019540095A JP 2020505044 A5 JP2020505044 A5 JP 2020505044A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- genetically modified
- protein
- composition
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022173206A JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762450917P | 2017-01-26 | 2017-01-26 | |
| US62/450,917 | 2017-01-26 | ||
| PCT/US2018/015180 WO2018140573A1 (en) | 2017-01-26 | 2018-01-25 | B-cell engineering |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173206A Division JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505044A JP2020505044A (ja) | 2020-02-20 |
| JP2020505044A5 true JP2020505044A5 (cg-RX-API-DMAC10.html) | 2020-12-17 |
Family
ID=62979713
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540095A Withdrawn JP2020505044A (ja) | 2017-01-26 | 2018-01-25 | Ｂ細胞操作 |
| JP2022173206A Pending JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173206A Pending JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Country Status (11)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| IL268110B2 (en) * | 2017-01-26 | 2024-01-01 | Sangamo Therapeutics Inc | B-cell engineering |
| EP3595681A4 (en) * | 2017-03-16 | 2020-12-16 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | TRANSPLANT CELL-BASED IMMUNOTHERAPY FOR LONG-PERIOD ADMINISTRATION OF THERAPEUTIC PROTEIN |
| CN114900773A (zh) | 2017-12-14 | 2022-08-12 | 弗洛设计声能学公司 | 声泳系统及其操作方法、控制声换能器及声学系统的方法 |
| JP7578590B2 (ja) | 2018-10-18 | 2024-11-06 | インテリア セラピューティクス，インコーポレーテッド | 第ｉｘ因子を発現するための組成物及び方法 |
| JP7656830B2 (ja) | 2019-11-01 | 2025-04-04 | 京都府公立大学法人 | Ｂ細胞抗体受容体、及びその利用 |
| EP4127188A4 (en) | 2020-03-31 | 2024-08-21 | Walking Fish Therapeutics | MODIFIED B CELLS AND METHODS OF USE THEREOF |
| WO2023192936A2 (en) * | 2022-03-30 | 2023-10-05 | Fred Hutchinson Cancer Center | Systems and methods to produce b cells that express selected antibodies and gene products |
| WO2024151683A2 (en) * | 2023-01-09 | 2024-07-18 | Walking Fish Therapeutics, Inc. | HUMAN B CELL ENGINEERED TO EXPRESS IgA AND IgM ANTIBODIES FOR THERAPEUTIC USE |
| WO2024196669A2 (en) * | 2023-03-17 | 2024-09-26 | Walking Fish Therapeutics, Inc. | Methods for in vivo editing of b cells |
| WO2024220447A2 (en) * | 2023-04-17 | 2024-10-24 | Be Biopharma, Inc. | Engineered cell preparations for treatment of niemann pick b disease |
| WO2026085108A2 (en) * | 2024-10-14 | 2026-04-23 | Immusoft Corporation | B cell compositions and methods of use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003901511A0 (en) * | 2003-03-28 | 2003-04-17 | Bionomics Limited | Nucleic acid molecules associated with angiogenesis II |
| ES2436741T3 (es) * | 2004-09-22 | 2014-01-07 | St. Jude Children's Research Hospital | Expresión mejorada de Factor IX en vectores de terapia génica |
| AU2010235161B2 (en) * | 2009-04-09 | 2015-01-22 | Sangamo Therapeutics, Inc. | Targeted integration into stem cells |
| EP2997146A4 (en) * | 2013-05-15 | 2017-04-26 | Sangamo BioSciences, Inc. | Methods and compositions for treatment of a genetic condition |
| WO2016014837A1 (en) * | 2014-07-25 | 2016-01-28 | Sangamo Biosciences, Inc. | Gene editing for hiv gene therapy |
| CN113699113A (zh) * | 2014-09-16 | 2021-11-26 | 桑格摩治疗股份有限公司 | 用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物 |
| EP4177336A1 (en) * | 2014-12-19 | 2023-05-10 | Immusoft Corporation | B cells for in vivo delivery of therapeutic agents |
| CA2981077A1 (en) * | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| EP3313441B1 (en) * | 2015-06-24 | 2024-02-21 | Janssen Biotech, Inc. | Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38 |
| CA2991301A1 (en) * | 2015-07-13 | 2017-01-19 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| EP3402533B1 (en) * | 2016-01-15 | 2021-08-04 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of neurologic disease |
| IL268110B2 (en) * | 2017-01-26 | 2024-01-01 | Sangamo Therapeutics Inc | B-cell engineering |
| MA49123A (fr) * | 2017-04-10 | 2020-03-25 | Immatics Biotechnologies Gmbh | Peptides et combinaison de peptides à utiliser en immunothérapie contre les leucémies et d'autres cancers |
| SG11201911729SA (en) * | 2017-06-16 | 2020-01-30 | Sangamo Therapeutics Inc | Targeted disruption of t cell and/or hla receptors |
| JP2020530997A (ja) * | 2017-08-08 | 2020-11-05 | サンガモ セラピューティクス， インコーポレイテッド | キメラ抗原受容体媒介性細胞標的化 |
| WO2019094725A2 (en) * | 2017-11-09 | 2019-05-16 | Sangamo Therapeutics, Inc. | Genetic modification of cytokine inducible sh2-containing protein (cish) gene |
| AU2019216269B2 (en) * | 2018-01-30 | 2025-05-01 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both T-cells and pathological cells and therapeutic antibody against said antigen |
| KR102879284B1 (ko) * | 2018-08-29 | 2025-10-31 | 난징 레전드 바이오테크 씨오., 엘티디. | 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도 |
| EP3887395A4 (en) * | 2018-11-30 | 2022-07-27 | Intima Bioscience, Inc. | METHODS FOR IDENTIFICATION OF IMMUNOMODULATORY GENES |
-
2018
- 2018-01-25 IL IL268110A patent/IL268110B2/en unknown
- 2018-01-25 CN CN201880021264.1A patent/CN110536963A/zh active Pending
- 2018-01-25 EP EP18744407.0A patent/EP3573464A4/en not_active Withdrawn
- 2018-01-25 BR BR112019015355A patent/BR112019015355A2/pt not_active IP Right Cessation
- 2018-01-25 CA CA3051113A patent/CA3051113A1/en active Pending
- 2018-01-25 MX MX2019008844A patent/MX2019008844A/es unknown
- 2018-01-25 JP JP2019540095A patent/JP2020505044A/ja not_active Withdrawn
- 2018-01-25 KR KR1020197023790A patent/KR20190111063A/ko not_active Ceased
- 2018-01-25 WO PCT/US2018/015180 patent/WO2018140573A1/en not_active Ceased
- 2018-01-25 AU AU2018212652A patent/AU2018212652B2/en not_active Ceased
- 2018-01-25 US US16/480,939 patent/US20190352614A1/en not_active Abandoned
-
2022
- 2022-10-28 JP JP2022173206A patent/JP2022191524A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xi et al. | Genetically engineered pigs for xenotransplantation: Hopes and challenges | |
| Wienert et al. | Wake-up sleepy gene: reactivating fetal globin for β-hemoglobinopathies | |
| Staal et al. | Autologous stem-cell-based gene therapy for inherited disorders: state of the art and perspectives | |
| JP2020500162A5 (cg-RX-API-DMAC10.html) | ||
| US12385070B2 (en) | Homology directed repair compositions for the treatment of hemoglobinopathies | |
| JP2016539627A5 (cg-RX-API-DMAC10.html) | ||
| De Ciuceis et al. | Immune mechanisms in hypertension | |
| Amelio et al. | p63 the guardian of human reproduction | |
| Kohn | Gene therapy for blood diseases | |
| JP2017504354A5 (cg-RX-API-DMAC10.html) | ||
| JP2021505187A (ja) | 遺伝子編集のためのｃｐｆ１関連方法及び組成物 | |
| Paladini et al. | The multifaceted nature of aminopeptidases ERAP1, ERAP2, and LNPEP: from evolution to disease | |
| Bueren et al. | Advances in the gene therapy of monogenic blood cell diseases | |
| ES3032739T3 (en) | Genetically engineered hematopoietic stem cell as a platform for systemic protein expression | |
| Naeimi Kararoudi et al. | Clustered regularly interspaced short palindromic repeats/Cas9 gene editing technique in xenotransplantation | |
| JP2021513338A5 (cg-RX-API-DMAC10.html) | ||
| Patel et al. | The immune response to the fVIII gene therapy in preclinical models | |
| Crossley et al. | Effective therapies for sickle cell disease: are we there yet? | |
| Ly et al. | Gene therapy in the treatment of heart failure | |
| Kyriakopoulou et al. | Gene editing innovations and their applications in cardiomyopathy research | |
| EP3765617A1 (en) | Systems and methods for the treatment of hemoglobinopathies | |
| Březina et al. | Mechanisms of direct and indirect presentation of self-antigens in the thymus | |
| Naldini et al. | The EHA research roadmap: hematopoietic stem cell gene therapy | |
| Wu et al. | Multiple gene modifications of pigs for overcoming obstacles of xenotransplantation | |
| Barbarani et al. | β-Hemoglobinopathies: the test bench for genome editing-based therapeutic strategies |